Skip to main content

Historical Bulking Agents

Several bulking agents that were widely used in earlier eras have been withdrawn or largely abandoned due to safety, efficacy, or regulatory concerns. They remain on the reconstructive radar because prior-treatment patients still present with sequelae.

Bovine Collagen (Contigen)​

GAX-collagen (glutaraldehyde-cross-linked bovine collagen) — marketed as Contigen — was the dominant urethral bulking agent in the 1990s and early 2000s.

  • Withdrawn in 2011 when the manufacturer discontinued production
  • Required pre-treatment skin testing for hypersensitivity
  • Efficacy waned rapidly over 1–2 years; frequent reinjection required
  • Patients with prior Contigen injections may present years later with durability loss and recurrent SUI — now reinjected with Bulkamid or progressed to sling

Polytetrafluoroethylene (PTFE / Teflon, Polytef)​

Used in the 1970s–1980s for both urethral bulking and VUR.

  • Particle migration to lung, brain, lymph nodes documented in animal and human studies
  • Granuloma formation at the injection site
  • Effectively abandoned for urologic bulking
  • Contemporary relevance is forensic — prior-Teflon patients with imaging abnormalities

Autologous Fat​

Injected as autologous adipose tissue — in theory biocompatible, inexpensive, available.

  • High rates of graft resorption (often >50% at 6 months) made durable bulking unreliable
  • Case reports of pulmonary fat embolism and death
  • Not currently used

Autologous Chondrocytes​

Culture-expanded autologous chondrocytes (from ear cartilage biopsy) suspended in a carrier.

  • Investigational in the early 2000s
  • Did not reach widespread clinical adoption
  • Superseded by allogeneic stem-cell and tissue-engineered approaches now under investigation

References​

Drawn from systematic-review coverage of historical agents in Hoe et al. 2021 and Hussain & Bray 2019 — see Bulkamid for full citations.

See also: Bulkamid, Macroplastique.